Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETNB 89BIO	$9.10 -0.4%	$9.93	$4.16 ▼ $11.84	$1.35B	1.28	2.09 million shs	1.55 million shs
RGNX REGENXBIO	$9.06 +1.5%	$8.67	$5.03 ▼ $13.48	$457.62M	1.11	976,762 shs	951,252 shs
SDGR Schrodinger	$19.45 -2.0%	$21.33	$16.60 ▼ $28.47	$1.43B	1.67	1.16 million shs	4.40 million shs
TARS Tarsus Pharmaceuticals	$54.14 +2.7%	$42.02	$24.95 ▼ $57.28	$2.29B	0.79	660,480 shs	513,652 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETNB 89BIO	+1.11%	-3.59%	-17.81%	+19.63%	+13.97%
RGNX REGENXBIO	+10.25%	+8.51%	+2.64%	+3.36%	-27.46%
SDGR Schrodinger	+5.25%	+2.59%	-6.15%	-15.07%	-0.35%
TARS Tarsus Pharmaceuticals	+2.65%	+26.43%	+26.94%	+21.20%	+99.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ETNB 89BIO	1.8595 of 5 stars	3.5	1.0	0.0	2.3	0.8	0.6
RGNX REGENXBIO	4.234 of 5 stars	3.4	3.0	4.6	1.6	2.5	0.6
SDGR Schrodinger	3.292 of 5 stars	3.4	3.0	0.0	3.2	3.3	0.6
TARS Tarsus Pharmaceuticals	1.7622 of 5 stars	2.5	1.0	0.0	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ETNB 89BIO	3.00	Buy	$26.29	188.85% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$28.38	213.19% Upside
SDGR Schrodinger	2.80	Moderate Buy	$31.20	60.41% Upside
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	23.14% Upside

Current Analyst Ratings Breakdown

Latest RGNX, TARS, ETNB, and SDGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	SDGR Schrodinger	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
8/8/2025	ETNB 89BIO	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$12.00 ➝ $11.00
8/8/2025	RGNX REGENXBIO	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $17.00
8/8/2025	RGNX REGENXBIO	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $37.00
8/8/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
7/29/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/14/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $30.00
7/12/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/3/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$28.00
6/27/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
6/11/2025	ETNB 89BIO	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ETNB 89BIO	N/A	N/A	N/A	N/A	$3.52 per share	N/A
RGNX REGENXBIO	$83.33M	5.49	N/A	N/A	$4.23 per share	2.14
SDGR Schrodinger	$207.54M	6.88	N/A	N/A	$4.67 per share	4.16
TARS Tarsus Pharmaceuticals	$295.52M	7.73	N/A	N/A	$7.88 per share	6.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ETNB 89BIO	-$367.08M	-$3.61	N/A	N/A	N/A	N/A	-94.48%	-80.92%	N/A
RGNX REGENXBIO	-$227.10M	-$3.44	N/A	N/A	N/A	-112.70%	-66.95%	-34.14%	N/A
SDGR Schrodinger	-$187.12M	-$2.48	N/A	N/A	N/A	-76.22%	-45.70%	-24.81%	N/A
TARS Tarsus Pharmaceuticals	-$115.55M	-$2.33	N/A	N/A	N/A	-31.13%	-32.36%	-21.04%	N/A

Latest RGNX, TARS, ETNB, and SDGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ETNB 89BIO	-$0.49	-$0.71	-$0.22	-$0.71	N/A	N/A
8/7/2025	Q2 2025	RGNX REGENXBIO	-$1.13	-$1.38	-$0.25	-$1.38	$40.87 million	$21.36 million
8/6/2025	Q2 2025	SDGR Schrodinger	-$0.83	-$0.59	+$0.24	-$0.59	$52.03 million	$54.76 million
8/6/2025	Q2 2025	TARS Tarsus Pharmaceuticals	-$0.33	-$0.48	-$0.15	-$0.48	$95.81 million	$102.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ETNB 89BIO	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ETNB 89BIO	0.07	15.19	18.03
RGNX REGENXBIO	N/A	3.13	3.13
SDGR Schrodinger	N/A	3.30	3.30
TARS Tarsus Pharmaceuticals	0.22	5.26	5.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ETNB 89BIO	N/A
RGNX REGENXBIO	88.08%
SDGR Schrodinger	79.05%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
ETNB 89BIO	2.60%
RGNX REGENXBIO	12.79%
SDGR Schrodinger	21.00%
TARS Tarsus Pharmaceuticals	8.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ETNB 89BIO	40	148.31 million	144.45 million	Optionable
RGNX REGENXBIO	370	50.51 million	44.05 million	Optionable
SDGR Schrodinger	790	73.38 million	57.97 million	Optionable
TARS Tarsus Pharmaceuticals	50	42.21 million	38.43 million	Optionable

RGNX, TARS, ETNB, and SDGR Headlines

Recent News About These Companies

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Sells $300,000.00 in Stock

August 14 at 7:54 AM | insidertrades.com

Informed Momentum Co LLC Decreases Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 14 at 5:47 AM | marketbeat.com

Stocks To Watch: Tarsus Pharmaceuticals Sees RS Rating Jump To 87

August 12 at 8:12 PM | msn.com

Blair William & Co. IL Sells 15,814 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 12 at 3:45 AM | marketbeat.com

HC Wainwright Brokers Raise Earnings Estimates for TARS

August 12 at 2:15 AM | americanbankingnews.com

Q3 EPS Forecast for Tarsus Pharmaceuticals Raised by Analyst

August 11 at 2:04 AM | marketbeat.com

Brokers Offer Predictions for TARS Q3 Earnings

August 11 at 2:04 AM | marketbeat.com

HC Wainwright Has Optimistic View of TARS FY2027 Earnings

August 10, 2025 | americanbankingnews.com

Analyst Estimates: Here's What Brokers Think Of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Second-Quarter Report

August 9, 2025 | finance.yahoo.com

FY2027 Earnings Forecast for TARS Issued By HC Wainwright

August 9, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $66.67 Average PT from Brokerages

August 9, 2025 | americanbankingnews.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 13.4% - What's Next?

August 8, 2025 | marketbeat.com

Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q2 2025 Result

August 7, 2025 | finance.yahoo.com

Tarsus targets 95,000–100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum

August 7, 2025 | msn.com

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Tarsus Pharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 7, 2025 | seekingalpha.com

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

August 6, 2025 | zacks.com

Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements

August 6, 2025 | globenewswire.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Rating of "Buy" from Brokerages

August 6, 2025 | marketbeat.com

Federated Hermes Inc. Lowers Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 5, 2025 | marketbeat.com

Jefferies Financial Group Inc. Has $4.05 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

August 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX, TARS, ETNB, and SDGR Company Descriptions

89BIO NASDAQ:ETNB

$9.10 -0.04 (-0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$9.10 +0.01 (+0.05%)

As of 04:20 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

REGENXBIO NASDAQ:RGNX

$9.06 +0.13 (+1.46%)

Closing price 04:00 PM Eastern

Extended Trading

$9.06 +0.00 (+0.06%)

As of 04:20 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Schrodinger NASDAQ:SDGR

$19.45 -0.39 (-1.97%)

Closing price 04:00 PM Eastern

Extended Trading

$19.48 +0.03 (+0.15%)

As of 04:27 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Tarsus Pharmaceuticals NASDAQ:TARS

$54.14 +1.42 (+2.69%)

Closing price 04:00 PM Eastern

Extended Trading

$55.78 +1.64 (+3.03%)

As of 04:26 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time